In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly and Merck Lead the Way With Asian FIPNet Strategies

Executive Summary

There's a new acronym to learn:FIPNet--for fully integrated pharmaceutical network. Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality research available in India and China--countries that also should prove to be a major source of future customers. Merck and Eli Lilly are two companies leading the FIPNet charge.

You may also be interested in...



Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride

Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.

Eli Lilly, Jubilant JV Called Off; Untimely Split Points At Rough Ride

Jubilant will absorb the joint venture as Lilly steps down, despite enthusiasm for Indian partnerships.

BGI Touts Eventual Merck Deal

Beijing Genomics and Merck intend to collaborate, using BGI resources primarily to analyze genomic and epigenetic data off of Merck samples. The announcement was more than just a shot across the bow signaling BGI's intent to dominate the gene sequencing services world. It could eventually extend into the clinical arena, which could open up another whole new collaborative - and competitive - area with the West.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV003120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel